Brainomix Receives £633,553 Funding
News Aug 25, 2015
Brainomix Limited has been awarded £633,553 by the Biomedical Catalyst (BMC), a joint programme run by the Medical Research Council (MRC) and Innovate UK. The funding is for two years and will support the development and validation of clinical decision-making support software designed to identify stroke patients who can benefit from mechanical reopening of a brain artery.
“We are very honoured to receive this award. We are now able to develop software that will empower physicians to identify stroke patients who benefit from the life-saving, but expensive treatment of mechanical clot removal,” said Dr Michalis Papadakis, Brainomix Chief Executive Officer.
The technology, called perfusion-ASPECTS, will automate the procedure to measure tissue at risk on brain CT scans and identify patients who can benefit from mechanical reopening of a brain artery. Worldwide, annually, 13,000,000 people suffer a stroke.
Recent studies show that mechanical clot removal improves patient outcome and the procedure is currently transforming stroke treatment. Patient selection is crucial for the adoption of this procedure because it costs up to £23,000 per patient.
Brainomix will build on its e-ASPECTS stroke damage measurement software to develop and validate perfusion-ASPECTS. The international reputation of the Brainomix founders in stroke will aid the successful development and clinical adoption of perfusion-ASPECTS.
Algorithm Unearths Over 1000 Antibiotic Proteins in a Few HoursNews
The algorithm identified 10 times more peptide variations than all previous discoveries combined, aiding the hunt for new antibiotics.READ MORE
Watch: Could Digital Microfluidics Revolutionise Experimentation?News
Technology using 'programmable droplets' could enable automated research on a grand scale.READ MORE
Toothpaste Ingredient Could Help Fight Drug-Resistant MalariaNews
An ingredient commonly found in toothpaste could be employed as an anti-malarial drug against strains of malaria parasite that have grown resistant to one of the currently-used drugs.READ MORE